A Phase 3 interventional study of N1539 and Intravenous Placebo in Pain, Post-operative, sponsored by Baudax Bio. Completed at 32 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-06-22.
Sponsored by Baudax Bio · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing meloxicam in Pain, Postoperative — 2 open to participants now, 3 under way, none of them phase 3. Meloxicam · Pain, Postoperative.
Among the 24 studies testing meloxicam in Pain, Postoperative, this one has the largest enrollment, is one of 3 that started in 2016, is one of 9 in phase 3, and was the 5th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.
Browse Pain, Postoperative studies →2 of the 24 studies testing meloxicam in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:
University of Oklahoma · Sites in United States
Ages 18–110
Beijing Tide Pharmaceutical Co., Ltd · Sites in China
Ages 18–70
By country, each count listing its studies:
Meloxicam: first FDA approval 2000 (MOBIC), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 722 is above the median of 75 across 4,829 interventional studies indexed under Pain, Postoperative.
Median enrollment 112 across the 24 interventional studies. Of the 20 that completed or were terminated, 19 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 24 have an industry lead sponsor. The 4 most frequent:
Baudax Bio is the lead sponsor of 11 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Baudax Bio has 9 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing meloxicam in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the safety and tolerability of N1539 in a variety of post-surgical conditions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects are eligible only if all the following apply:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
N1539 (Intravenous meloxicam) 30mg every 24 hours for up to 7 doses.
Drug: N1539
IV Placebo every 24 hours for up to 7 doses.
Drug: Intravenous Placebo
Also known as: Intravenous meloxicam
Number of Subjects With Adverse Events
Number of subjects reporting 1 or more treatment-emergent adverse events
Time frame: 28 Days
Investigator Satisfaction With Surgical Wound Healing
Investigators assessed their satisfaction with the healing of the surgical wound according to an 11-point numeric rating scale (0-10) where a score of 0 was completely unsatisfied (worse outcome), and a score of 10 was completely satisfied (better outcome).
Time frame: Up to 7 days after last study dose
Postoperative Opioid Use
Postoperative opioid use was measured throughout the inpatient phase and converted to the total IV morphine equivalent dose
Time frame: Up to 7 days
| Milestone | N1539 30 mg | IV Placebo |
|---|---|---|
| Started | 539 | 183 |
| Treated | 538 | 183 |
| Completed treatment | 519 | 177 |
| Completed | 526 | 180 |
| Not completed | 13 | 3 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Lost to follow-up | 8 | 3 |
| Withdrew: Subject unable to return for visit | 1 | 0 |
Number of subjects reporting 1 or more treatment-emergent adverse events
| Participants | N1539 30 mg | IV Placebo |
|---|---|---|
| Number of Subjects With Adverse Events | 339 | 119 |
Investigators assessed their satisfaction with the healing of the surgical wound according to an 11-point numeric rating scale (0-10) where a score of 0 was completely unsatisfied (worse outcome), and a score of 10 was completely satisfied (better outcome).
| score on a scale | N1539 30 mg | IV Placebo |
|---|---|---|
| One day after last study dose/Discharge | 9.5 ± 0.88 | 9.4 ± 0.97 |
| 7 Days after last study dose | 9.3 ± 1.18 | 9.4 ± 0.86 |
Postoperative opioid use was measured throughout the inpatient phase and converted to the total IV morphine equivalent dose
| mg (IV Morphine Equivalent Dose) | N1539 30 mg | IV Placebo |
|---|---|---|
| Day 1 (Hour 0-24) | 17.0 ± 22.10 | 21.8 ± 24.70 |
| Day 2 (Hour 24-48) | 8.6 ± 19.15 | 11.3 ± 21.82 |
| Day 3 (Hour 48-72) | 4.1 ± 16.60 | 6.2 ± 21.83 |
| Day 1-2 (Hour 0-48) | 25.3 ± 36.96 | 32.7 ± 41.44 |
| Day 1-3 (Hour 0-72) | 27.4 ± 44.67 | 35.9 ± 52.77 |
| During Treatment | 28.8 ± 57.39 | 37.5 ± 66.06 |
Collected over AE data were collected from the time of first study dose, through the last study contact, 28 days following the last study dose.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| N1539 30 mg | 0/538 (0%) | 14/538 (2.6%) | 227/538 (42.2%) |
| IV Placebo | 0/183 (0%) | 10/183 (5.5%) | 85/183 (46.4%) |
| Event | N1539 30 mg | IV Placebo |
|---|---|---|
| Post procedural pulmonary embolismInjury, poisoning and procedural complications | 3/538 | 0/183 |
| Coronary artery diseaseCardiac disorders | 0/538 | 1/183 |
| Jejunal stenosisGastrointestinal disorders | 0/538 | 1/183 |
| NauseaGastrointestinal disorders | 0/538 | 1/183 |
| Hepatocellular injuryHepatobiliary disorders | 0/538 | 1/183 |
| Abdominal abscessInfections and infestations | 0/538 | 1/183 |
| Postoperative abscessInfections and infestations | 0/538 | 1/183 |
| Anastomotic ulcerInjury, poisoning and procedural complications | 0/538 | 1/183 |
| Incisional herniaInjury, poisoning and procedural complications | 0/538 | 1/183 |
| Postoperative ileusInjury, poisoning and procedural complications | 1/538 | 1/183 |
| Event | N1539 30 mg | IV Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 123/538 | 50/183 |
| ConstipationGastrointestinal disorders | 51/538 | 17/183 |
| VomitingGastrointestinal disorders | 27/538 | 14/183 |
| HeadacheNervous system disorders | 20/538 | 12/183 |
| PruritusSkin and subcutaneous tissue disorders | 21/538 | 10/183 |
| Gamma-glutamyltransferase increasedInvestigations | 21/538 | 5/183 |
| Alanine aminotransferase increasedInvestigations | 11/538 | 7/183 |
| DizzinessNervous system disorders | 15/538 | 7/183 |
| AnaemiaBlood and lymphatic system disorders | 18/538 | 4/183 |
| InsomniaPsychiatric disorders | 9/538 | 6/183 |
All Treated Subjects (Safety Analysis Set)
| Age, Categorical(Participants) | N1539 30 mg | IV Placebo | Total |
|---|---|---|---|
| <=18 years | 2 | 0 | 2 |
| Between 18 and 65 years | 416 | 140 | 556 |
| >=65 years | 120 | 43 | 163 |
| Age, Continuous(years) | N1539 30 mg | IV Placebo | Total |
|---|---|---|---|
| Mean | 52.9 ± 13.56 | 53.0 ± 13.77 | 53.0 ± 13.60 |
| Sex: Female, Male(Participants) | N1539 30 mg | IV Placebo | Total |
|---|---|---|---|
| Female | 315 | 113 | 428 |
| Male | 223 | 70 | 293 |
| Ethnicity (NIH/OMB)(Participants) | N1539 30 mg | IV Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 76 | 29 | 105 |
| Not Hispanic or Latino | 462 | 154 | 616 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | N1539 30 mg | IV Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 7 | 4 | 11 |
| Native Hawaiian or Other Pacific Islander | 2 | 0 | 2 |
| Black or African American | 68 | 21 | 89 |
| White | 459 | 155 | 614 |
| More than one race | 1 | 3 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | N1539 30 mg | IV Placebo | Total |
|---|---|---|---|
| United States | 502 | 168 | 670 |
| Canada | 5 | 3 | 8 |
| New Zealand | 8 | 2 | 10 |
| Australia | 23 | 10 | 33 |
| Advanced Age (>65) with Impaired Renal Function (GFR<90)(Participants) | N1539 30 mg | IV Placebo | Total |
|---|---|---|---|
| Count of participants | 88 | 31 | 119 |
| Surgery Site/Type(Participants) | N1539 30 mg | IV Placebo | Total |
|---|---|---|---|
| Orthopedic | 273 | 93 | 366 |
| Abdominal/Pelvic | 254 | 87 | 341 |
| Spinal | 10 | 3 | 13 |
| Other | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Mar 2016 to primary completion in Mar 2017, 12 months.
Results were first posted in May 2023, 6 years 2 months after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 12 months is close to that.
Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Meloxicam
Baudax Bio